Eisai Innovation, Inc. Golden Ticket 2025
Eisai Innovation and MBC BioLabs Announce 2025 Eisai Golden Ticket Competition to Accelerate Early Drug Discovery and Research Efforts
Eisai Innovation, Inc. (EII), an affiliate of Eisai Co., Ltd. the fully integrated pharmaceutical company based in Tokyo, Japan, is partnering with MBC BioLabs to award one Golden Ticket to an innovative life science startup. Eisai is interested in drug discovery platform technologies, novel targets and biology that can be utilized in oncology and neurology.
The winner of Eisai’s Golden Ticket receives:
- One-year free lab space at MBC BioLabs’ facility
- Access to the shared amenities and services provided at MBC BioLabs’ facility
- Special access to scientific and business leaders at Eisai
To apply, submit your non-confidential company presentation below. The deck should be a maximum of 10 slides and includes an appendix for any supplemental information.
Please include the following information in your company’s presentation:
- A one-page executive summary of your company
- Your company’s mission
- Key science or technology
- Targeted disease(s), patient populations or issues in healthcare
- Management Team, including advisors
- Non-confidential Intellectual Property or publications that include data supporting your science or technology
- Key milestones, including development and financing
- The competitive landscape
The deadline to apply for Eisai’s Golden Ticket is September 5, 2025.
If you have any questions, please email: GoldenTicket@eisaiinnovation.com.
About Eisai Innovation, Inc.
Eisai Innovation, Inc. (EII) is Eisai’s strategic investment organization aspiring to identify synergies between the scientific community and the Eisai network of companies. EII has provided equity investments to early-stage companies which develop cutting-edge drug discovery technologies, novel targets and innovative healthcare solutions.
For more information about Eisai Innovation, Inc. please visit www.eisaiinnovation.com.
About Eisai
Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.
In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.
For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook.
For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.
